Insider Selling: Replimune Group (NASDAQ:REPL) Insider Sells 5,208 Shares of Stock

Replimune Group, Inc. (NASDAQ:REPL) insider Christopher Sarchi sold 5,208 shares of the business’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $9.10, for a total transaction of $47,392.80. Following the sale, the insider directly owned 123,088 shares in the company, valued at approximately $1,120,100.80. The trade was a 4.06% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Replimune Group Price Performance

Shares of REPL traded up $0.25 during trading hours on Wednesday, reaching $8.99. The stock had a trading volume of 1,895,576 shares, compared to its average volume of 4,388,618. Replimune Group, Inc. has a 12 month low of $2.68 and a 12 month high of $17.00. The stock has a market capitalization of $705.18 million, a PE ratio of -2.60 and a beta of 0.80. The company has a debt-to-equity ratio of 0.26, a quick ratio of 6.31 and a current ratio of 6.31. The company’s 50-day moving average is $6.56 and its two-hundred day moving average is $7.39.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.03). Research analysts expect that Replimune Group, Inc. will post -2.97 EPS for the current year.

Institutional Trading of Replimune Group

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Readystate Asset Management LP lifted its position in shares of Replimune Group by 1,296.2% in the 3rd quarter. Readystate Asset Management LP now owns 2,621,012 shares of the company’s stock worth $10,982,000 after purchasing an additional 2,433,292 shares during the period. Braidwell LP raised its stake in Replimune Group by 550.3% during the third quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock worth $11,523,000 after buying an additional 2,327,205 shares during the last quarter. Balyasny Asset Management L.P. lifted its holdings in Replimune Group by 507.4% in the third quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock valued at $11,012,000 after buying an additional 2,195,448 shares during the period. Erste Asset Management GmbH lifted its holdings in Replimune Group by 13,597.5% in the third quarter. Erste Asset Management GmbH now owns 1,630,000 shares of the company’s stock valued at $7,074,000 after buying an additional 1,618,100 shares during the period. Finally, Nuveen LLC bought a new stake in Replimune Group during the first quarter valued at $6,546,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Wedbush upgraded Replimune Group from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $4.00 to $18.00 in a report on Monday, October 20th. BMO Capital Markets downgraded shares of Replimune Group from an “outperform” rating to an “underperform” rating and cut their target price for the stock from $27.00 to $2.00 in a research report on Wednesday, July 23rd. Jefferies Financial Group reduced their target price on shares of Replimune Group from $31.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, July 22nd. Barclays downgraded shares of Replimune Group from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $17.00 to $3.00 in a research note on Wednesday, July 23rd. Finally, JPMorgan Chase & Co. raised shares of Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 price objective on the stock in a research note on Monday, October 20th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $9.75.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.